I finally got an opportunity to listen | INSM Message Board Posts

Insmed Incorporated

  INSM website
  • Membership Drive Update: In the first 48 hours we've hit almost 20% of our goal. An encouraging start to be sure, but we can't stop now. We need to pull enough subscription revenue forward to counter severe cash flow deficits resulting from a dramatic slow-down in ad spend thanks to the global pandemic which shows no signs of letting up in the near-term. We're doing everything in our power to keep our heads above some very choppy water, but we can't do it alone. We need your help. So if you've ever thought about giving our premium service a try, there's no better time to do it than right now by taking advantage of one of our discounted multi-year plans. Thanks in advance for your continued loyalty & support! 

  • Limited Premium Membership Offer
    Choose a Plan, Save Money & Help Us Survive the Pandemic

    Lifetime @ $399 (only 24 left)  5-yrs @ $199 (only 31 left)  2-yrs @ $99 (only 29 left)

INSM   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  53433 of 53596  at  9/17/2020 2:25:20 AM  by

walkabout

The following message was updated on 9/17/2020 2:38:49 AM.

 In response to msg 53425 by  zake1
view thread

Re: I finally got an opportunity to listen

So after listening to this broadcast, one feels kind of stunned numb at the potentials.

Arikayce is well on its way to to be a wildly successful franchise, and it's just getting started, and the market is clearly larger than initially anticipated, plus we have COVID exasperating NTM and similarly affected patients, which swings open the door even further. This market alone is already in multi-billions arena, and no competition in sight.

Then there is Brensocatib (INS1007), which if sails through a successful P3, then not sure what other reference in history, that exist one can compare the financial potentials to grasp the extent of what could materialize, if and when Europe and Asia (including China) come online. Okay... I'll throw out a number, which in hindsight does not seem that crazy => $100 billion? Can anyone ballpark this? And oh... no competition in sight. And all the infrastructure built up and in place from Arikayce will be available to rapidly channel Brensocatib worldwide. Wow!

Then there is Treprostinil Palmitil (INS1009), which we do not know too much about yet, but more will be unveiled upon Sept. 30 Research Day., but clearly WL is excited about it. I dug a bit into this.

According to: "Worldwide Pulmonary Arterial Hypertension (PAH) Markets: Size, Share & Trends Analysis Report 2019-2026", the global pulmonary arterial hypertension market size is expected to reach USD 9.3 billion by 2026. It is projected to progress at a CAGR of 5.6% during the forecast period. The cases of PAH are rising in the range of 100,000 to 200,000 per year. However, in the past few years, the occurrence of this disorder has intensified due to the risk factors such as alcohol/tobacco consumption, HIV, sedentary lifestyle, smoking, and other idiopathic conditions.

There appears are product competition in this space, but WL alluded the novel nature of INS1009 could be a game changer.

IMHO, Historian's $180/sh * 10 is likely what is in the cards for the patient (pun intended) folks. I think us longs qualify since most of us have held for a decade or more. But... Finally, finally we are on a path of ascension. Now... just gotta hang-on and not pull the trigger too soon. LOL...



     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 4     Views: 178
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
53434 Re: I finally got an opportunity to listen insmhistorian 0 9/17/2020 6:55:36 AM






Financial Market Data provided by
.


Loading...